@BharatBiotech Updates
BBV154 (Nasal COVID vaccine) has received approval for phase 3 clinical trials.
The trials will evaluate BBV154 nasal vaccine for both the 2 dose primary schedule and booster dose schedule. #COVIDVaccine@tapasjournalist— DD News (@DDNewslive) January 28, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


